Evidence method
Level · gp.fundamentals.debt_to_revenue
262.20% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Sep 30, 2017
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001144204-17-055663General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
5.15% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
35.47% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
25.02% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
79.89% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
56.24% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
19.37% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
5.47% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.04% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 277.86%
- Current
- 262.20%
- Delta
- -15.66%
- Previous
- 5.15%
- Current
- 5.15%
- Delta
- 0.00%
- Previous
- 0.00%
- Current
- 35.47%
- Delta
- 35.47%
- Previous
- 42.85%
- Current
- 25.02%
- Delta
- -17.83%
- Previous
- 94.51%
- Current
- 79.89%
- Delta
- -14.62%
- Previous
- 52.81%
- Current
- 56.24%
- Delta
- 3.42%
- Previous
- 15.62%
- Current
- 19.37%
- Delta
- 3.75%
- Previous
- 4.84%
- Current
- 5.47%
- Delta
- 0.63%
- Previous
- 3.97%
- Current
- 3.04%
- Delta
- -0.94%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIP MARGIN_INCREASED →Transitioned To · ANIP PROFITABILITY_INCREASED →Transitioned To · ANIP R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIP SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.